Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Ovarian Neoplasms

Free Subscription 20.05.2019 2 Am J Obstet Gynecol 2 Cancer Res 1 Clin Cancer Res 7 Gynecol Oncol 2 Hum Pathol 1 Int J Oncol 1 J Natl Cancer Inst 2 Lancet Oncol 1 Obstet Gynecol 1 Oncology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Obstet Gynecol

1. UCCELLA S, Nero C, Vizza E, Vargiu V, et al
   Sentinel-Node Biopsy in Early Stage Ovarian Cancer: Preliminary Results of a Prospective Multicentre Study (SELLY).
   Am J Obstet Gynecol. 2019 May 10. pii: S0002-9378(19)30660.
   PubMed     Text format     Abstract available
   
   
2. MANNING-GEIST BL, Hicks-Courant K, Gockley AA, Clark RM, et al
   A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
   Am J Obstet Gynecol. 2019 May 10. pii: S0002-9378(19)30661.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

3. DORAYAPPAN KDP, Gardner ML, Hisey CL, Zingarelli RA, et al
   A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer.
   Cancer Res. 2019 May 16. pii: 0008-5472.CAN-18-3538.
   PubMed     Text format     Abstract available
   
   
4. TRAVERS M, Brown SM, Dunworth M, Holbert CE, et al
   DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer.
   Cancer Res. 2019 May 14. pii: 0008-5472.CAN-18-4018.
   PubMed     Text format     Abstract available
   
   

   
   Clin Cancer Res

5. FUCIKOVA J, Rakova J, Hensler M, Kasikova L, et al
   TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer.
   Clin Cancer Res. 2019 May 10. pii: 1078-0432.CCR-18-4175.
   PubMed     Text format     Abstract available
   
   

   
   Gynecol Oncol

6. PUECHL AM, Edwards J, Suri A, Nakayama J, et al
   The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
   Gynecol Oncol. 2019;153:74-79.
   PubMed     Text format     Abstract available
   
   
7. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
   En bloc pelvic resection for ovarian carcinomatosis: Hudson procedure in 10 steps.
   Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31471.
   PubMed     Text format    
   
   
8. JERZAK KJ, Duska L, MacKay HJ
   Endocrine therapy in endometrial cancer: An old dog with new tricks.
   Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31518.
   PubMed     Text format     Abstract available
   
   
9. MANNING-GEIST BL, Alimena S, Del Carmen MG, Goodman A, et al
   Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?
   Gynecol Oncol. 2019;153:63-67.
   PubMed     Text format     Abstract available
   
   
10. LIANG J, Wolsiefer K, Zestcott CA, Chase D, et al
    Implicit bias toward cervical cancer: Provider and training differences.
    Gynecol Oncol. 2019 Feb 7. pii: S0090-8258(19)30055.
    PubMed     Text format     Abstract available
    
    
11. FILIPPOVA OT, Chi DS, Long Roche K, Sonoda Y, et al
    Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
    Gynecol Oncol. 2019 May 8. pii: S0090-8258(19)31185.
    PubMed     Text format     Abstract available
    
    
12. TOMAO F, Musacchio L, Di Mauro F, Boccia SM, et al
    Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    Gynecol Oncol. 2019 May 9. pii: S0090-8258(19)30504.
    PubMed     Text format     Abstract available
    
    

    
    Hum Pathol

13. PRAT J, D'Angelo E, Espinosa I
    Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
    Hum Pathol. 2018 Jun 23. pii: S0046-8177(18)30230.
    PubMed     Text format     Abstract available
    
    
14. PARK JK, Otsuka N, Tomaru U, Suzuki H, et al
    Clinicopathological significance of PSF3 expression in uterine endometrial carcinomas.
    Hum Pathol. 2018 Jun 21. pii: S0046-8177(18)30220.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

15. JIANG S, Chang H, Deng S, Fan D, et al
    Icariin enhances the chemosensitivity of cisplatinresistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Int J Oncol. 2019;54:1933-1942.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

16. VOS JR, Fakkert IE, de Hullu JA, van Altena AM, et al
    Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    J Natl Cancer Inst. 2019 May 11. pii: 5488012. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

17. VERGOTE I, Scambia G, O'Malley DM, Van Calster B, et al
    Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2019 May 7. pii: S1470-2045(19)30178.
    PubMed     Text format     Abstract available
    
    
18. SECORD AA
    Ovarian cancer: time to move beyond one size fits all.
    Lancet Oncol. 2019 May 7. pii: S1470-2045(19)30285.
    PubMed     Text format    
    
    

    
    Obstet Gynecol

19. WRIGHT JD, Huang Y, Melamed A, Tergas AI, et al
    Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer.
    Obstet Gynecol. 2019 May 9. doi: 10.1097/AOG.0000000000003288.
    PubMed     Text format     Abstract available
    
    

    
    Oncology

20. LALISCIA C, Cosio S, Morganti R, Mazzotti V, et al
    Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy.
    Oncology. 2019;96:235-241.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: